September 2019 - 4D Lifetest™ is revolutionizing Single Cell Gel Electrophoresis (SCGE)

Paper News 1 small

With the recently published paper it is now officially documented that 4D Lifetest™ is revolutionizing Single Cell Gel Electrophoresis in vitro and makes it reliable enough to address cancer diagnostic applications. The outstanding performance of 4D Lifetest™ solves the most important problem of overlapping viability so far limiting the use of COMET Assays to academic research projects.
It successfully approves the highly innovative character of 4D Lifetest™ and allows now to proceed to the next important milestone, the Proof of Concept for in vivo diagnostics.

 

 

An online preprint has been published by the end of August by ALTEX (impact factor 5.4):

 

„A Novel Approach to Increase Robustness, Precision and High-Throughput Capacity of Single Cell Gel Electrophoresis”

 Juan C. Cassano1, Matthias Roesslein1, Rolf Kaufmann2,3, Thomas Luethi2, Oliver Schicht4, Peter Wick1 and Cordula Hirsch1
1Particles-Biology Interactions Laboratory, Empa, Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland; 2Centre for X-ray Analytics, Empa, Swiss Federal Laboratories for Materials Science and Technology, Duebendorf, Switzerland; 3current address: Schaer Proton AG, Flaach, Switzerland; 44D Lifetec AG, Cham, Switzerland

 

Conclusions:

“The technological high-throughput electrophoresis solution presented here solves one of the key issues of Single Cell Gel Electrophoresis (SCGE) variability. The achieved precision together with a reduction in sample number and processing time on a high Throughput (HT) level will not only decrease costs but also facilitate the application of SCGE for diagnostic purposes. In the near future, the combination with reliable automated acquisition and analysis software solutions will offer a precise and reproducible HT SCGE platform for the generation of new prognostic outputs.”

 

Paper News Grafics 2

 

 

Graph E and F show the improvement of precision and sensitivity of the 4D Lifetest™ (novel) and a commercially available solution on the market (platform).

 

Read here the online preprint published by the end of August by ALTEX (impact factor 5.4) or download the scientific paper as a PDF here and the supplements as a PDF here.

 

Thus, our innovation now has been officially qualified to meet the high expectations announced and revolutionize the possible applications of SCGE. Passing this milestone is a highly important success for 4D Lifetec and its investors on the way to reach the market and make 4D Lifetest™ available as Liquid Biopsy Assay for the early detection of cancer as fast as possible. Even more important 4D Lifetest™ is now ready for its clinical validation in patients affected by different types of cancer.